97817-23-7Relevant articles and documents
Preparation 2 - amino - 5 - CBZ - 4, 5, 6, 7 - tetrahydro-thiazolo [5, 4 - C] pyridine of the new method (by machine translation)
-
Paragraph 0012; 0014, (2019/01/23)
The invention discloses a process for preparing 2 - amino - 5 - CBZ - 4, 5, 6, 7 - tetrahydro-thiazolo [5, 4 - C] pyridine of the new method, comprises the following steps: N - tert-butoxycarbonyl - 4 - piperidone in pyridine with sulfur and single cyanamide mixed heating reaction→cooling→filtering→washed with an organic solvent, and dried to obtain a pale yellow solid product→in dichloromethane in trifluoroacetic acid is mixed with low-temperature reaction, concentrated→with triethylamine in dichloromethane in the mixed low-temperature drop chlorination benzyl formate, stirring reaction→[...]→dichloromethane extraction, the organic phase water, salt water washing, drying, filtering and concentrated to obtain crude product→ethyl acetate beating, the final product is obtained yellow solid. The invention of cheap price for raw materials to replace the original high price of the raw material for preparing the final product, to avoid the original ring-brominated by-product when many routes, not only the operation is simple, convenient purification, the cost is reduced, high yield, favorable to the industrialized production and cost control. (by machine translation)
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation
Wang, Zhengyu,Shi, Xiaofan,Zhang, Huan,Yu, Liang,Cheng, Yanhua,Zhang, Hefeng,Zhang, Huibin,Zhou, Jinpei,Chen, Jing,Shen, Xu,Duan, Wenhu
, p. 128 - 152 (2017/08/10)
Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.
Heterocycylic-substituted quinoline-carboxylic acids
-
, (2008/06/13)
1-Substituted-6-fluoro-7-heterocyclic-1,4-dihydroquino-1-(or dihydronaphthyridin)-4-one carboxylic acids have antibacterial properties. The 7-heterocyclic group is a bicyclic group, one of the rings of which is saturated and the other ring of which is unsaturated.